Nicolas Rouyrre

机构：Novartis (Switzerland) · ORCID：0000-0002-7847-0235

发表论文 36 篇 · 总被引 2159 次 · h-index 15

代表论文

• Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 study (2015 · The Lancet · 被引 1294)
• Phase I Dose Escalation and Pharmacokinetic Study of BI 2536, a Novel Polo-Like Kinase 1 Inhibitor, in Patients With Advanced Solid Tumors (2008 · Journal of Clinical Oncology · 被引 159)
• Efficacy of everolimus plus octreotide LAR in patients with advanced neuroendocrine tumor and carcinoid syndrome: final overall survival from the randomized, placebo-controlled phase 3 RADIANT-2 study (2017 · Annals of Oncology · 被引 125)
• Meta-analysis of stomatitis in clinical studies of everolimus: incidence and relationship with efficacy (2016 · Annals of Oncology · 被引 90)
• Abstract CT-01: BYL719, a next generation PI3K alpha specific inhibitor: Preliminary safety, PK, and efficacy results from the first-in-human study (2012 · Cancer Research · 被引 62)
• Immunogenicity and safety of low-dose intradermal rabies vaccination given during an Expanded Programme on Immunization session in Viet Nam: results of a comparative randomized trial (1999 · Transactions of the Royal Society of Tropical Medicine and Hygiene · 被引 58)